Details

Autor(en) / Beteiligte

• Chandesris, Marie-Olivia
• Damaj, Gandhi
• Canioni, Danielle
• Brouzes, Chantal
• Lhermitte, Ludovic
• Hanssens, Katia
• Frenzel, Laurent
• Cherquaoui, Zoubair
• Durieu, Isabelle
• Durupt, Stéphane
• Gyan, Emmanuel
• Beyne-Rauzy, Odille
• Launay, David
• Faure, Cyril
• Hamidou, Mohamed
• Besnard, Sophie
• Diouf, Momar
• Schiffmann, Aurélie
• Niault, Mathilde
• Jeandel, Pierre-Yves
• Ranta, Dana
• Gressin, Remi
• Chantepie, Sylvain
• Barete, Stéphane
• Dubreuil, Patrice
• Bourget, Philippe
• Lortholary, Olivier
• Hermine, Olivier

Titel

Midostaurin in Advanced Systemic Mastocytosis

Ist Teil von

• The New England journal of medicine, 2016-06, Vol.374 (26), p.2605-2606

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• To the Editor: Advanced systemic mastocytosis 1 carries a poor prognosis. 2 Midostaurin, an inhibitor of tyrosine kinases, targets KIT mutants associated with mastocytosis. 3 The French National Reference Center for Mastocytosis (CEREMAST) conducted a prospective survey of patients with mastocytosis who were treated with midostaurin under a transitory-use authorization program. All the patients provided written informed consent. From August 2012 through April 2015, a total of 28 patients with mastocytosis (including 4 with aggressive disease, 18 with associated hematologic non–mast-cell disease, 3 with mast-cell leukemia, 1 with mast-cell sarcoma, and 2 with progressive smoldering disease) received midostaurin at a dose of 100 . . .